Understanding how proteins interact in cancer cells over time
Mapping Dynamic Changes in Protein Interactome using Proximity Labeling with High Temporal Resolution
['FUNDING_OTHER'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-11064422
This study is looking at how proteins in cancer cells interact with each other in real-time, using new tools to find important processes that could help develop better treatments for cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-11064422 on ClinicalTrials.gov |
What this research studies
This research focuses on mapping the dynamic interactions between proteins in cancer cells, which can change rapidly within minutes. By developing advanced tools that enhance the sensitivity and temporal resolution of current methods, the project aims to identify critical biological processes and potential therapeutic targets for cancer treatment. The approach utilizes a technique called biotin proximity labeling, allowing researchers to detect even weakly associated protein complexes in living cells. This could lead to a better understanding of how cancer signals are transmitted and how they can be disrupted.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from novel therapeutic strategies.
Not a fit: Patients with non-cancerous conditions or those not currently undergoing cancer treatment may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets and improved treatments for cancer patients.
How similar studies have performed: Previous research has shown promise in using similar biotin proximity labeling techniques to study protein interactions, indicating potential for success in this novel application.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KARGINOV, ANDREI V — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: KARGINOV, ANDREI V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy